Nyxoah SA (NYXH)
NASDAQ: NYXHHealth CareMedical/Dental InstrumentsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
NYXH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $137.48M
- EPS (TTM)
- -$2.56
- Dividend yield
- None
- 52-week range
- 1.26 – 6.88
- Day range
- 1.33 – 1.39
- Volume / Avg
- 87.94K / 275.85K
- Beta
- —
- Shares outstanding
- 101.84M
- Next earnings
- Nov 5, 2026
52-week range
NYXH stock today
Shares of Nyxoah SA (NYXH) finished lower on Oct 8 at $1.35, a drop of 4.93% or $0.07 per share, versus the S&P 500's 0.47% decline. Trading was light, with 87.94K shares changing hands, about 32% of the average daily volume. Shares are 80.4% below their 52-week high of $6.88, set on Oct 10, 2025 and 7.1% above the 52-week low of $1.26, near the bottom of the past year's range.
NYXH is down 70.7% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 77.9%. Nyxoah SA has posted a net loss over the last twelve months (EPS of -$2.56), so its P/E ratio is not meaningful. Nyxoah SA's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Nyxoah SA
Company profileNyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Olivier Taelman
- Headquarters
- Mont-Saint-Guibert
- Employees
- 153
- IPO year
- 2021
- Website
- nyxoah.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$4.20+211.11%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
NYXH news
All NYXH newsNyxoah SA peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRMDKORU Medical Systems Inc. | 3.00 | +0.67% | $137.80M | vs NYXH |
| LUCDLucid Diagnostics Inc. | 0.6501 | +4.27% | $124.14M | vs NYXH |
| QTEXQTREX Quantum Ltd. | 1.69 | +1.81% | $113.36M | vs NYXH |
| STIMNeuronetics Inc. | 2.14 | -1.38% | $163.06M | vs NYXH |
| PYPDPolyPid Ltd. | 4.90 | -1.01% | $99.53M | vs NYXH |
| APYXApyx Medical Corporation | 2.36 | -7.45% | $99.41M | vs NYXH |
| LNSRLENSAR Inc. | 6.45 | -0.92% | $79.24M | vs NYXH |
| LUNGPulmonx Corporation | 1.81 | -1.63% | $77.74M | vs NYXH |
Indexes, lists and sector
Nyxoah SA stock FAQ
What is Nyxoah SA's stock price today?
NYXH last traded at $1.35 as of Oct 8, 4:00 PM EDT, down 4.93% on the day. Prices are delayed at least 15 minutes.
When is Nyxoah SA's next earnings date?
Nyxoah SA is expected to report earnings on Thursday, November 5, 2026.
Who is Nyxoah SA's CEO?
Mr. Olivier Taelman is the chief executive officer of Nyxoah SA, which has about 153 employees.
What is the NYXH 52-week high?
The 52-week high for NYXH is $6.88 and the 52-week low is $1.26. The stock is currently 80.4% below its high.